None listed
Conditions
Brief summary
Overweight individuals typically possess metabolic and vascular problems. Most overweight individuals have high levels of fat and sugar in their blood and also typically carry a lot of fat around their abdomen. Overweight individuals also possess problems in their arteries and veins which become stiff and are unable to stretch easily. Thus, the purpose of the study is to examine cardiovascular function following green tea supplement and its combination with exercise both acutely and chronically. It is hypothesised that (1) green tea supplement will reduce cardiovascular dysfunction in overweight males; (2) a combination of green tea supplement and exercise will normalize cardiovascular dysfunction possessed by the overweight males.
Interventions
The project will be investigating the effect of green tea capsules (GTC) acutely (one off ingestion of GTC) and chronically (8 weeks ingestion of GTC) on vascular health. Also the ingestion of GTC and its interaction with moderate intensity of exercise will be examined. A double blinded cross over design will be used in the study. Both acute and chronic settings will consist of two different interventional arms; ingestion of GTC (arm 1) and GTC plus exercise (arm 2). In the acute and chronic set
The project will be investigating the effect of green tea capsules (GTC) acutely (one off ingestion of GTC) and chronically (8 weeks ingestion of GTC) on vascular health. Also the ingestion of GTC and its interaction with moderate intensity of exercise will be examined. A double blinded cross over design will be used in the study. Both acute and chronic settings will consist of two different interventional arms; ingestion of GTC (arm 1) and GTC plus exercise (arm 2). In the acute and chronic settings, the dose of GTC will be 1500 mg of GTC containing 375 mg of epigallocatechin gallate (EGCG), which will be taken orally in the morning. The exercise intensity for both settings will be at 65% of maximal oxygen uptake (VO2max) for 30 minutes. Thus, in the acute setting, cardiovascular function will be assessed following ingestion of one GTC (arm 1) then a week later (following a one week of wash out period) participants will perform exercise on a bike following ingestion of GTC (arm 2). In a chronic setting, participants will be provided GTC for the duration of 8 weeks. The GTC (1500 mg of GTC containing 375 mg of EGCG) will be taken orally once in the morning for 8 weeks (arm 1). Cardiovascular function then will be assessed at pre, 4 weeks, and 8 weeks post ingestion of GTC. Following one week of wash out, participants will ingest GTC every morning plus perform one-on-one sessions of supervised moderate intensity exercise at 65% of VO2max for 30 minutes, 3 times/week for 8 weeks (arm 2). Cardiovascular function then will be assessed at pre, 4 weeks, and 8 weeks post GTC plus exercise.
Sponsors
University of New South Wales
Study design
Allocation
Randomised controlled trial
Primary purpose
Prevention
Eligibility
Sex/Gender
Male
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
The criteria for study entry is a body mass index (BMI) between 25-35 kg/m2 and not to be involved in regular exercise (eg., exercise 4-5 times per week at hard intensity for more than 4 years).
Exclusion criteria
All subjects who are on medication that influences cardiovascular and autonomic function and those who are diseased (eg., youthful cardiac events) will be screened out of the study.
Outcome results
None listed